<DOC>
	<DOCNO>NCT01594398</DOCNO>
	<brief_summary>The purpose study evaluate effect food pharmacokinetics ( PK ) experimental drug , entinostat , woman breast cancer men woman non-small cell lung cancer . The safety tolerability entinostat also evaluate entinostat give well approve drug , exemestane ( Aromasin® ) erlotinib ( Tarceva® ) . A biomarker ( chemical `` marker '' blood/tissue may relate response study drug ) also test .</brief_summary>
	<brief_title>Study Assess Food Effect Pharmacokinetics Entinostat Subjects With Breast Cancer Non-Small Cell Lung Cancer</brief_title>
	<detailed_description>This Phase 1 , randomize , open-label , study entinostat . The study design evaluate food effect pharmacokinetics entinostat . Patients randomize receive entinostat without food Cycle 1 Day 1 ( C1D1 ) . Patients randomize receive entinostat food C1D1 receive second dose entinostat without food Cycle 1 Day 15 ( C1D15 ) . Patients randomize receive entinostat without food C1D1 receive second dose entinostat food C1D15 . Each cycle study 28 day duration . Blood sample obtain pre-dose serial blood sample take dose assess pharmacokinetics . For Cycle 2 subsequent cycle , patient continue receive entinostat Days 1 15 cycle . Those breast cancer also receive exemestane orally daily start Cycle 2 Day 1 . Those NSCLC also receive erlotinib start Cycle 2 Day 1 . Patients assess screen pre-prescribed time study enrollment use standard assessment . Patients also assess tumor response 2 cycle . Patients continue receive study treatment tumor progression adverse event occur necessitate discontinuing therapy determine Investigator .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Exemestane</mesh_term>
	<mesh_term>Entinostat</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<criteria>Breast Cancer Patients Only Postmenopausal female patient Histologically cytologically confirm ER+ breast cancer initial diagnosis current disease progression candidate receive exemestane NSCLC Patients Only : Cytologically histologically confirm NSCLC stage IIIb IV Received 1 2 prior chemotherapy chemoradiotherapy regimen advance NSCLC ( exclude erlotinib valproic acid ) disease progression candidate receive erlotinib All Patients : Age ≥ 18 year Patient must follow laboratory parameter study screen : Hemoglobin ≥ 9.0 g/dL ; unsupported platelet ≥ 100.0 109/L ; ANC ≥ 2.0 x 109/L ; Creatinine le 2.5 time upper limit normal institution ; AST alanine transaminase ( ALT ) &lt; 2.5 time upper limit normal institution Patients may history brain metastasis long certain criterion meet Pregnant lactate woman Patient rapidly progressive lifethreatening metastasis . Patient previous treatment entinostat HDAC inhibitor include valproic acid Patient concomitant medical condition precludes adequate study treatment compliance assessment , increase patient risk opinion investigator , limited : MI arterial thromboembolic event within 6 month , experience severe unstable angina , New York Heart Association ( NYHA ) Class III IV disease QTc interval &gt; 0.47 second . Uncontrolled heart failure hypertension , uncontrolled diabetes mellitus , uncontrolled systemic infection . Patients another active cancer ( exclude adequately treat basal cell carcinoma cervical intraepithelial neoplasia [ CIN / cervical carcinoma situ ] melanoma situ ) . Prior history cancer allow , long active disease within prior 5 year .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>carcinoma , non small cell lung</keyword>
	<keyword>lung disease</keyword>
	<keyword>lung neoplasm</keyword>
	<keyword>Respiratory</keyword>
	<keyword>Carcinoma , Bronchogenic</keyword>
	<keyword>Bronchial Neoplasms</keyword>
	<keyword>Respiratory Tract Neoplasms</keyword>
	<keyword>Thoracic Neoplasms</keyword>
	<keyword>Neoplasms Site</keyword>
	<keyword>Respiratory Tract Diseases</keyword>
	<keyword>Erlotinib</keyword>
	<keyword>Protein Kinase Inhibitors</keyword>
	<keyword>Breast Neoplasms</keyword>
	<keyword>Neoplasms</keyword>
	<keyword>Breast Diseases</keyword>
	<keyword>Exemestane</keyword>
	<keyword>Aromatase Inhibitors</keyword>
</DOC>